Portola Pharmaceuticals, Inc.

269 articles with Portola Pharmaceuticals, Inc.

• 

  Aria Deploys AI Differently to Drive New Insights

  1/17/2022

  Aria Pharmaceuticals is using a unique computational approach to drug development that has increased its success rate by 30-fold when compared to traditional approaches.
• 

  Former Portola CEO Takes the Helm at T-Cell Cancer Therapy Company

  3/5/2021

  Scott Garland, the former chief executive officer of Portola Pharmaceuticals, will become the next CEO of South San Francisco-based PACT Pharma.

• Alexion Completes Acquisition of Portola

  7/2/2020

  Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). The acquisition adds Factor Xa inhibitor reversal agent Andexxa ® [coagulation factor Xa (recombinant), in

• 

  How COVID-19 is Affecting Clinical Trials and Drug Supplies from Biotech Bay Companies

  6/5/2020

  Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.

• Portola Pharmaceuticals Announces Virtual 2020 Annual Stockholder Meeting

  5/18/2020

  Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of stockholders, employees and other meeting participants, the location and format of its 2020 Annual Stockholder Meeting

• U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year

  5/14/2020

  - Reinforcing Breakthrough Innovation and Clinical Value of Andexxa, Proposed Extension Will Support Patient Access by Continuing to Provide Medicare Reimbursement in the Hospital Setting -   [14-May-2020]   SOUTH SAN FRANCISCO, Calif. , May 14, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid

• Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

  5/11/2020

  - Reached Agreement to be Acquired by Alexion; Transaction Expected to Close in Third Quarter - - Andexxa®/Ondexxya® Global Net Product Revenues of $25.6 Million -   [11-May-2020]   SOUTH SAN FRANCISCO, Calif. , May 11, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today reported financial results for the three months ended March 

• SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Portola Pharmaceuticals, Inc. - PTLA

  5/6/2020

  Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Portola Pharmaceuticals, Inc. relating to the sale of the Company to Alexion Pharmaceuticals, Inc.

• SHAREHOLDER ALERT: WeissLaw LLP Investigates Portola Pharmaceuticals, Inc.

  5/6/2020

  WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Portola Pharmaceuticals, Inc. in connection with the proposed acquisition of the Company by Alexion Pharmaceuticals, Inc.

• ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Portola Pharmaceuticals, Inc.

  5/5/2020

  Rowley Law PLLC is investigating potential securities law violations by Portola Pharmaceuticals, Inc. and its board of directors concerning the proposed acquisition of the company by Alexion Pharmaceuticals, Inc. Stockholders will receive $18.00 for each share of Portola Pharmaceuticals stock that they hold.

• Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion

  5/5/2020

  Portola Pharmaceuticals, Inc.® announced that it is cancelling its webcast and conference call to discuss the Company's financial results for the first quarter ended March 31, 2020 that was previously scheduled for Monday, May 11, 2020, at 4:30 p.m. ET.

• Alexion to Acquire Portola

  5/5/2020

  Expands and diversifies Alexion’s hematology, neurology and critical care commercial portfolio with transformative Factor Xa inhibitor reversal agent

• 

  Alexion Set to Acquire Portola Pharmaceuticals in $1.41 Billion Deal

  5/5/2020

  Alexion said the acquisition of Portola will bolster its commercial portfolio and create long-term value for its shareholders.

• Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 1, 2020

  5/1/2020

  Portola Pharmaceuticals, Inc.® announced that on April 30, 2020, the Compensation Committee of the Board of Directors approved, effective as of April 30, 2020, the grant to five new employees of inducement stock options to purchase an aggregate of 10,700 shares of common stock, and awards of 5,350 restricted stock units in the aggregate.

• Portola Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 11, 2020

  4/23/2020

  Portola Pharmaceuticals, Inc.® announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended March 31, 2020, and provide a general business overview, on Monday, May 11, 2020, at 4:30 p.m. ET..

• Portola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020

  4/7/2020

  Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that the Centers for Medicare & Medicaid Services (CMS) established a new permanent J-code for Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo] facilitating reimbursement in the hospital outpatient setting. The code, J7169 (Injection, c

• Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 1, 2020

  4/1/2020

  Portola Pharmaceuticals, Inc.® announced that on March 31, 2020, the Compensation Committee of the Board of Directors approved, effective as of March 31, 2020, the grant to eight new employees of inducement stock options to purchase an aggregate of 16,100 shares of common stock, and awards of 8,050 restricted stock units in the aggregate.

• Portola Pharmaceuticals Announces Proactive Steps Supporting Public Health Efforts to Combat Coronavirus (COVID-19)

  3/18/2020

  Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced proactive steps the Company is taking in support of public heath efforts to prevent furtherspread of coronavirus (or COVID-19) around the globe.

• Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds

  3/16/2020

  Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced new data reinforcing the value of Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only FDA-approved reversal agent for the Facto

• New Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors

  3/5/2020

  Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the presentation of new data demonstrating that using Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] to treat patients with intracranial hemorrhage (ICH) associated with the oral Factor Xa inhibitors apixaban or rivaroxaban is projected to provide a net reduction in costs to an acute care hospital